Abstract Despite advances in the treatment of breast cancer between 10 to 15% of patients develop cutaneous metastatic disease (CMD) most frequently on the face, neck and chest wall, usually in later stages of the disease as a harbinger of metastasis that will occur in other organs 1 to 3 years later. CMD is not life threatening but can significantly impact patients’ quality of life and is a cause of anxiety, pain, discomfort, and a portal for infection. CMD could also be a seed for metastases at other sites. Surgery or radiotherapy is used for single or localized CMD. Topical (epicutaneous) therapy with molecularly targeted agents provides an attractive modality for treatment of more widespread breast CMD. PHT-427 is a dual pleckstrin homology (PH) domain inhibitor of PDPK and AKT, two key enzymes of PI3K signaling that is frequently activated in breast cancer. We report here PHT-427's topical activity in CMD. MCF-7 human breast cancer (mutant PIK3CA) 106 cells in 20 μI were injected intradermaly in the flank of estradiol pelleted female nu/nu mice. When tumors reached 40-200 mm3 groups of 5 mice were treated twice a day with 0.1 ml vehicle or vehicle with 50 mg/ml PH-427, applied to a 1 cm patch of skin over the tumor. Mice were housed individually with collars to prevent them ingesting applied drug. After 10 days mice were euthanized 4 hr after the last application and blood, tumor and overlying skin were removed for analyses. Topical PHT-427 gave 89 % inhibition of tumor growth (p = 0.017, 3/5 no measurable tumor). There was no change in body weight and no apparent skin toxicity. Western blotting showed that PHT-427 inhibited p-AKT Thr308/Ser473 in skin and tumor, and decreased total AKT in skin but not tumor. p-PDPK1 Ser241 was inhibited in tumor but not skin, as was the downstream target pPKC Thr410 and pMAPK Thr202/Tyr204. Measurement of PHT-427 by HPL-MS showed very high levels in the skin at the site of application, levels of ∼50 μg/g in tumor and 5.5 μg/ml in plasma. In vitro levels of PHT-427 of 5 μg/ml are required for killing of sensitive cell lines. Thus, topical application of PHT-427 can deliver active drug levels to skin and tumor, inhibiting PDPK1 and AKT, and significantly inhibiting tumor growth without adverse effects on normal skin. Topical PHT-427 could have use in skin conditions driven by PDPK/AKT such as prevention of sun damage and skin cancer, and in the personalized therapy of breast CMD. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4481. doi:10.1158/1538-7445.AM2011-4481
Read full abstract